BOCA RATON, Fla, March 03, 2016 -- RxStrategies, Inc. is pleased to announce the appointment of Russell Crane to the new position of Sales Manager - Northeast Region. He joins the RxStrategies’ sales team and has responsibility for sales and delivery of customized 340B pharmacy administration and split billing solutions to providers located in the Northeast Region.
"I am very pleased to welcome Russell to the RxStrategies’ team,” said Fenton Markevich, Chief Executive Officer for RxStrategies. “We look forward to incorporating Russell’s market and product expertise and knowledge for the benefit of our existing and future clients. We believe that Russell will be a strong addition and will complement our current market facing sales and account management teams.”
Russell joins RxStrategies with strong pharmacy industry background, with a particularly strong presence in the Northeast in market facing roles to the pharmacy administration and 340B markets. Russell is a graduate of Northeastern University.
"RxStrategies has a strong reputation in the marketplace with both a unique and transparent processing solution, and a proprietary split billing solution for this complex market," said Crane. "I am excited to join a growing industry leader and bring value to clients and prospects by using a consultative approach. I look forward to continuing that tradition by providing 340B guidance and insight to our current and future clients."
About RxStrategies, Inc.
Established in 2003 and headquartered in Boca Raton, Florida, RxStrategies, Inc. provides accountability, transparency and value-based solutions for the Federal 340B Drug Pricing Programs. As a full-service 340B Drug Pricing Program services organization, RxStrategies provides a diverse range of services to all “Qualified Entities” and the in-house and/or contract pharmacies, including 340B administration, split billing, orphan drug, and audit services. RxStrategies’ “real-time” comprehensive solutions are designed to meet the challenges of regulatory compliance, patient eligibility, pharmacy replenishment, program tracking and reporting of the Federal 340B Drug Pricing Program. To learn more, please visit www.340Bplus.com.
Media Contact: Cheryl Musial, Media Relations, Mopdog, Inc. [email protected] 678-737-7325


Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Instagram Outage Disrupts Thousands of U.S. Users
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



